Loading...

EXAI - Exscientia plc

Analyst Downgrade Signal for 01-05-2024
Analyst Downgrade Signal: EXAI from Buy to Neutral by BofA Securities
Price Target: $11>>9


Loading Chart EXAI

Stock Signal Information


Signal

Analyst Downgrade Signal: EXAI from Buy to Neutral by BofA Securities
Price Target: $11>>9
Report Date: 01-05-2024
Symbol: EXAI - Exscientia plc
Sector: Healthcare
Industry: Biotechnology
Analyst Downgrade Signal: EXAI from Buy to Neutral by BofA Securities
Price Target: $11>>9

  EXAI Technical Analysis

Company Contact

Exscientia plc (EXAI)
The Schrödinger Building
Oxford,
Phone: 44 13 8220 2136
Website: http://www.exscientia.ai
CEO:

EXAI, Exscientia plc

EXAI Exscientia plc Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. It offers end-to-end solution of artificial intelligence and technologies for target identification, drug candidate design, translational models, and patient selection. Its platform allows to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.